Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective

The U.S. Food and Drug Administration recently marked 10 years since first updating the labeling for warfarin (often referred to as the “poster child” of pharmacogenomics) to include information regarding the potential impact of CYP2C9 and VKORC1 genetic variation on warfarin dosing requirements and...

Descripción completa

Detalles Bibliográficos
Autores principales: Drozda, Katarzyna, Pacanowski, Michael A., Grimstein, Christian, Zineh, Issam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
TRANSLATIONAL PERSPECTIVE
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6115648/
https://www.ncbi.nlm.nih.gov/pubmed/30175278
http://dx.doi.org/10.1016/j.jacbts.2018.06.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6115648/
https://www.ncbi.nlm.nih.gov/pubmed/30175278
http://dx.doi.org/10.1016/j.jacbts.2018.06.001

Ejemplares similares